Characterization and analysis of oncofetal tRNA and its possible application for cancer diagnosis and therapy

Insights

Tumor cells exhibit undermodified tRNAs, particularly affecting queuosine (Q) and Y base. These modifications, especially the G-tRNA to Q-tRNA conversion, show promise for cancer diagnosis and therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tumorigenesis is associated with alterations in tRNA modifications.
  • Specific modified nucleosides, like queuosine and Y base, are implicated in cancer.
  • Understanding tRNA structure and function is crucial for cancer research.

Purpose of the Study:

  • To determine the primary structures of tumor-specific tRNAs and their normal counterparts.
  • To investigate the role of tRNA modifications in tumorigenesis.
  • To explore the potential of modified nucleosides as cancer biomarkers and therapeutic targets.

Main Methods:

  • Postlabeling RNA-sequencing to analyze tRNA primary structures.
  • Chemical synthesis of Q base analogs.
  • Administration of Q base to tumor-bearing mice.

Main Results:

  • Tumor-specific tRNAs are characterized by undermodification of hypermodified nucleosides in the anticodon loop.
  • Hydroxy Y base and queuosine are significantly affected in tumor cells.
  • G-tRNA levels decrease with cell differentiation, indicating a link to cell state.
  • Exogenous Q base administration effectively converts G-tRNA to Q-tRNA in tumor cells.

Conclusions:

  • tRNA undermodification is a hallmark of tumor cells.
  • Modified nucleosides like Y base and Q base are potential biomarkers for cancer detection.
  • Q base analogs show potential as diagnostic tools and chemotherapeutic agents for cancer treatment.

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...